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ABSTRACT
Contrary to the commonly held misconception, bone is a
relatively dynamic organ that undergoes significant
turnover as compared to other organs in the body. This
review details how complex intercellular signalling,
between the osteoprogenitor cells and mature osteo-
blasts, osteocytes and osteoclasts, regulates and
balances activities of bone cells during remodelling and
growth. Both systemic, as well as local autocrine and
paracrine factors are discussed. A number of recent
important advances in cell biology of bone have led to a
new paradigm in understanding of the subject. In this
regard, the interaction between the immune system and
bone cells is of particular interest, leading to the
emergence of a new discipline termed osteoimmunology.
The role of lymphocytes and a number of key cytokines in
the regulation of osteoclastogenesis and osteoblast
function is critically examined. The intracellular signalling
regulating key cellular pathways involved in cell differ-
entiation and activity are outlined. The emerging evidence
of osteocytes as mechanosensors as well as regulators of
mineralisation is discussed.
Bone is a specialised connective tissue hardened by
mineralisation with calcium phosphate in the form
hydroxyapatite ([Ca3(PO4)2]Ca(OH)2). Bone has
well recognised mechanical functions: it provides
rigidity and shape, protection and support for body
structures, and aids locomotion. Contrary to popular
belief, bone is in fact a highly dynamic structure
undergoing constant remodelling. This bone turn-
over allows the bone to repair itself, for example
after fracture, and to adapt to the forces placed on it.
In childhood there is a very high rate of bone
turnover in which formation exceeds resorption. In
young adulthood, formation and resorption are in
approximate balance, but with ageing there is a net
loss of bone. The rate of bone turnover, collagen
matrix, size, structure, geometry and density all
combine to determine the bone’s overall mechanical
properties. Defects in these parameters will result in
diseases such as osteoporosis, Paget’s disease of bone,
osteopetrosis and osteogenesis imperfecta.
In order for the strength of the bone to be
maintained, the process of bone turnover must be
carefully regulated. This review will discuss the
systemic and local regulatory mechanisms, as well
as the cell–cell interactions involved in bone develop-
ment, morphogenesis and remodelling. The emerging
role of osteocytes as a pivotal player in the control of
osteoblast and osteoclast function will be described,
along with recent insights into the role of the
immune system in the regulation of bone turnover.
BONE STRUCTURE AND CELL TYPES
The skeleton is comprised of long bones, such as
humerus, femur and tibia, and flat bones, such as
skull, scapula and ileum. There are two main
histological types of mature bone: cortical or
compact bone which has a dense, ordered structure
and cancellous or trabecular bone which is lighter,
less compact and has an irregular structure.
Cortical or compact bone is found mainly in the
shaft of long bones and the surfaces of flat bones. It
is composed of bone laid down concentrically
around central canals known as Haversian sys-
tems. These contain blood vessels, lymphatics,
nerves and connective tissue. A concentric layer of
rings or lamellae of bone matrix surround each
Haversian canal. Within the lamellae are tiny
spaces called lacunae containing osteocytes.
Trabecular or cancellous bone is less numerous
and forms the ends of long bones and the inner
parts of flat bones. It contains interconnecting
plates and bars called trabeculae, with intervening
marrow lending it a honeycomb appearance. The
trabeculae are aligned along lines of stress; this
connectivity adds considerably to its strength. The
specific anatomical distribution of cortical and
trabecular bone reflects their respective compres-
sive and tensile strengths. Thus trabecular bone is
ideally suited to withstanding compressive stress
and hence is the predominant bone in vertebrae.
A further important element in the structure of
bone is the collagen network. In adults, collagen
fibres adopt a preferential orientation resulting in
the formation of lamellar bone. In cortical bone the
lamellae are concentrically arranged, and in trabe-
cular bone they are parallel to one another. Woven
bone is formed in the growing skeleton and in
various pathological conditions in the adult. This
type of bone has a random arrangement of collagen
fibres, with non-uniformly sized and distributed
osteocytes.
In general each bone has an outer layer of
cortical bone overlying trabecular bone and the
medullary cavity. The cortical bone has an outer
membrane called the periosteum. The periosteum
has two layers: an outer fibrous layer and an inner
one, which has osteogenic potential and lays down
new bone allowing the bone to enlarge, a process
known as periosteal apposition. The inner surface
of the cortex has another lining called the
endosteum (fig 1). Bone tends to undergo resorp-
tion from the endosteal surface. Both the perios-
teum and endosteum contain osteoblasts and
osteoclasts and their progenitors. Osteoblasts and
osteoclasts function in a coordinated manner, by
their respective bone forming and resorbing activ-
ities, to carry out remodelling, growth and repair.
THE CYCLE OF BONE TURNOVER
The basic multicellular unit of bone comprises the
osteocytes, osteoclasts and osteoblasts. Its activity
of the unit is regulated by mechanical forces, bone
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cell turnover, hormones (e.g. parathyroid hormone (PTH),
growth hormone (GH)), cytokines and local factors. The
activation process is at least partly regulated by the osteocytes,
which detect mechanical stress and respond to biochemical
stimuli. Activation results in the lining cells of the endosteal
surface being retracted, and digestion by matrix metalloprotei-
nases of the endosteal collagenous membrane. Osteoclasts are
then recruited, followed by fusion of activated osteoclasts to
become multinucleated osteoclasts. Activated osteoclasts med-
iate resorption of the underlying bone. Subsequently, osteo-
blasts are recruited to the resorption cavity and lay down new
osteoid, which eventually becomes calcified; this process is
completed in approximately 3–6 months (fig 2). The rate of
bone turnover varies according to the type of bone, being
highest in sites where trabecular bone predominates such as
vertebrae and lowest at sites high in cortical bone such as the
hip.
DIFFERENTIATION AND LOCAL REGULATION OF BONE CELLS
Osteoblasts
Considerable progress has been made in identifying morpho-
gens, signalling pathways and transcriptional regulators med-
iating differentiation of mesenchymal stem cells into
osteoprogenitors (fig 3). During skeletal development osteoblast
differentiation and deposition of bone matrix occurs, and
involves spatiotemporal coordination of interaction among
diverse endocrine, paracrine and autocrine factors. Osteoblast
differentiation is stimulated by several factors at different stages
of differentiation. Thus, epidermal growth factor promotes
renewal of mesenchymal stem cells; self renewal has been found
to be critically dependent on the expression of certain genes,
such as stem cell antigen 1 (Sca-1/Ly- 6A).1 2 Osteoblast
stimulating facor (OSF-)-1, also known as pleiotrophin (PTN)
or heparin-binding growth-associated molecule (HB-GAM), is
chemotactic for the osteoprogenitor and stimulates mature
osteoblast activity.3 4 Other factors such as PTH, GH, prosta-
glandins and insulin-like growth factor-1 (IGF-1) exhibit more
pervasive effects by affecting renewal of mesenchymal stem
cells (MSC) and stimulating osteogenic differentiation of bone
morphogenetic protein (BMP)-primed cell populations.
The development of the skeleton, like many other tissues,
involves complex spatiotemporally regulated molecular interac-
tion between Wnt/catenin and transforming growth factor-b/
BMP mediated signalling pathways. The expression of Runx2, a
key osteoblast differentiation transcription factor, is required
for multipotent MSC to differentiate into osteoblastic lineage.
Runx2 also inhibits the differentiation of MSC into adipocytic
and chondrocytic lineages. BMP2 and WNT pathways jointly
promote RUNX2 expression to promote osteoblast differentia-
tion.
Canonical Wnt pathway
Wingless-ints (Wnts), secreted lipid-modified glycoproteins,
activate three distinct intracellular signalling pathways, includ-
ing the Wnt/b-catenin pathway, which is commonly referred to
as the canonical Wnt pathway (fig 4).5–10 Genetic studies in
human and animal models suggest that the canonical Wnt
pathway, together with BMP signalling and key transcription
factor RUNX2(CBFA1/AML3), has an important role in skeletal
development, osteoblast differentiation and bone formation.11–19
A member of the lipoprotein receptor family, low-density
lipoprotein receptor-related protein 5 (LRP5), plays a critical role
in canonical Wnt signalling by forming a frizzled/LRP5/6
receptor complex, and Wnts activate the canonical pathway
by interacting with receptors of the frizzled family and co-
receptors of the LRP5/6 family.20 The importance of LRP5 has
been shown by the observations that activating and inactivating
mutations of the gene resulted in high bone mass and the
osteoporosis-pseudoglioma syndrome respectively.21–23
Wnt signal transduction involves stabilisation of b-catenin by
inhibiting GSK-3-mediated b-catenin phosphorylation.
Unphosphorylated b-catenin accumulates, and translocates to
the nucleus, binds LEF/TCF transcription factors and activates
the transcription of downstream genes (fig 4).10 b-catenin2/2
transgenic mice revealed an essential role of Wnt signalling in
osteoblast differentiation.12 24 25 Dickkopf family members
(Dkk1 and Dkk2) and secreted frizzled related proteins (Sfrps)
are families of extracellular proteins that negatively modulate
canonical Wnt signalling; Sfrps bind directly to Wnts and
prevent their association with Lrp and Fzd receptors.26–35 Dkks
limit the availability of Lrp5/6 receptors to Wnts by sequester-
ing Lrp5/6 into complexes with the transmembrane protein
Kremens (Kringle-containing protein marking the eye and the
nose) and may promote its lysosomal destruction (fig 4);
Kremens have high affinity for Dkk.36 37 Sclerostin, a SOST gene
product, shares many characteristics with the Wnt antagonist
dickkopf-1 in antagonising BMP-stimulated bone formation and
BMP- and Wnt-induced Wnt activation. Sclerostin inhibits
BMP-stimulated bone formation, but does not affect BMP
signalling.38–45 Instead, it antagonises Wnt signalling in osteo-
blastic cells. High bone mass in sclerosteosis and van Buchem
disease may, therefore, result from increased Wnt signalling.
In the absence of Wnt signalling, b-catenin is phosphorylated
by glycogen synthase kinase 3 (GSK3), which promotes its
ubiquitination (U) by E2 ligases and degradation by the
proteosome.46 47 The scaffolding proteins (Axin, Frat and
Figure 1 Schematic diagram of
architecture of cortical bone, as found in
long bones (A); and trabecular bone, as in
vertebrae (B).
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Dishevelled (Dsh)) mediate the degradation of phosphorylated
b-catenin by creating docking sites for F-box protein/E2 ligase
complexes.48–51 Wnt signalling prevents b-catenin degradation,
b-catenin then enters the nucleus where it displaces corepressors
(CoR) from T cell-factor/lymphoid-enhancer-factor (Tcf/Lef)
and recruits transcriptional co-activators to stimulate expres-
sion of many genes; such as those involved in cycle progression
(e.g. cyclin D1) and survival (e.g. c-myc) (an updated list of
genes modulated by Wnt signalling is available on: http://www.
stanford.edu/,rnusse/wntwindow.html).
Bone morphogenetic proteins
There are at least 30 bone morphogenetic proteins (BMPs) that
form the largest group of the TGF (transforming growth
factor)-b superfamily.52–55 They are so named for their osteo-
inductive properties, and regulate differentiation of mesenchy-
mal cells into components of bone, cartilage or adipose tissue.52
TGF-b/BMP ligand signal is mediated by heterodimeric receptor
serine/threonine protein kinases (receptor types 1 and 2) and a
family of receptor substrates (the Smad proteins) that move
into the nucleus. Once activated, receptor kinases phosphor-
ylate R-Smads (receptor-regulated Smads), and phosphorylated
R-Smads then complex with C-Smads (common-mediator
Smads). The complexes, which act as transcriptional regulators,
then translocate into the nucleus.54 55 All Smads recognise and
have low affinity interaction with the same sequence; high
affinity interaction is facilitated by other transcriptional
cofactors including OAZ, Mixer, and Milk.55 BMP-2 and BMP-
7 induce the critical transcription factors Runx2 and Osterix in
mesenchymal stem cells and promote osteoblast differentia-
tion.56 57
RUNX2 and osterix
During development of the skeleton and formation of bone
tissue, Wnt/b-catenin and TGF-b/BMP pathways modulate key
transcriptional factor RUNX2(CBFA1/AML3) to induce the
osteogenic phenotype.15–21 RUNX2, a member of the runt
homology domain transcription factor family is essential for
osteoblast differentiation and is also required for embryonic
bone formation. The Runx family has three members, Runx1/
Cbfa2/Pebp2aB, Runx2/Cbfa1/Pebp2aA and Runx3/Cbfa3/
Pebp2aC. They all have a runt domain that is a DNA-binding
homologue of Drosophila pair-rule gene runt.58 Runx proteins
interact with transcriptional co-activator core binding factor b
(Cbfb)/polyoma enhancer binding protein 2b (Pebp2b) forming
a heterodimer; and Cbfb is also required for Runx2-dependent
osteoblast and chondrocyte differentiation.19 20 59 Runx22/2
transgenic mice have complete lack of both endochondral and
intramembranous ossification due to the absence of osteoblast
differentiation.16 17 While Runx2 is essential for differentiation
of mesenchymal cells into osteoblasts, both Runx2 and Runx3
are essential for chondrocyte maturation, and hence endochon-
dral ossification.60 Runx2 however inhibits differentiation of
Figure 2 Osteoblast and osteoclast activities in the cycle of bone
turnover.
Figure 3 Osteoblast differentiation from
stem cell involves coordinated interaction
among diverse endocrine, paracrine and
autocrine factors. SC, stem cell; MSC,
mesenchymal stem cell; OB, osteoblast.
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mesenchymal cells into adipocytes and chondrocytes.60 61 Runx2
triggers the expression of major bone matrix protein genes,
including the Col1a1, osteopontin and osteocalcin genes at an
early stage of osteoblast differentiation and its actions sustain a
supply of preosteoblasts.
Osterix, a member of the SP family of transcription factors is
a second transcription factor that is essential for osteoblast
differentiation.62 Osterix2/2 and Runx22/2 mice have similar
phenotypes; both show complete lack of endochondral and
intramembranous ossification due to the absence of osteoblast
differentiation. Osterix is believed to act downstream of Runx2,
since mesenchymal cells from osterix2/2 mice express Runx2,
but osterix is not expressed in Runx22/2 mice.62 Osterix2/2
mesenchymal cells retain the ability to differentiate into
chondrocytes.62 Both RUNX2 and osterix expression in mature
osteoblasts are modulated by intracellular immunophilin
mediated calcineurin/NFATc1 pathway and enhance alkaline
phosphatase and Col1a1 promoter activity.63
To summarise, b-catenin directs osteoblast differentiation at
the preosteoblast stage, bcatenin/TCF1 enhances Runx2 expres-
sion and its promoter activity. Runx2 is required for mesench-
ymal progenitor cell differentiation into preosteoblasts, and for
suppressing their differentiation into adipocytes and chondro-
cytes. Osterix and b-catenin act by directing the differentiation
of preosteoblasts into immature osteoblasts and abolish the
potential of preosteoblasts for differentiating into chondrocytes.
Runx2 transcriptional regulators
Many proteins interact with and modulate Runx2 activity.
Cbfb is considered a critical regulator of Runx2, as it is required
for DNA binding of Runx2. Nevertheless, Runx2 retains limited
function even in the absence of Cbfb, implying that as yet
unidentified factors may substitute for Cbfb. Runx2 activity is
enhanced by a number of transcription factors, including ATF4,
C/EBPb, C/EBPd, ETS1, Grg5, Menin, p204, Rb, Smad1, Smad5
and TAZ. It is inhibited by others including C/EBPd, Dlx3,
Msx2, PPARg, Smad3, Stat1, TLE, Twist and Yes.64–66 Twist-1, a
member of the basic helix–loop–helix (bHLH) family of
proteins, is expressed in embryological mesodermal and cranial
neural crest cells during embryogenesis.67 Expression of Twist-1
has been associated with the inhibition of differentiation for
multiple mesenchymal cell lineages, including bone.68–70 Twist-1
interacts directly with Runx2, and this causes gene inactivation
in osteoblast precursors.70 Id1, an internal dominant negative
form of HLH transcription factor l, induces Twist-1 degradation
and alleviates the inhibitory effect of Twist-1.71 Inhibition of
BMP signalling by Twist-1 is enhanced by E-protein, indicating
that Twist-1 and Id1 regulate differentiation of mesenchymal
cell lineages by controlling BMP signalling.72 73
Osteocytes
Osteoblasts are encased by the matrix that they themselves
synthesise and become osteocytes. Osteocytes, found dispersed
throughout the bone matrix, are terminally differentiated cells
that have much lower bone forming activity than osteoblasts,
but constitute over 90% of adult bone cells.74 Despite their
relative inactivity compared with osteoblasts, osteocytes play a
central role in the determination and maintenance of bone
structure.75–79 The bone matrix isolates osteocytes from each
other and instead osteocytes interact with other osteocytes and
bone cells by an elaborate network of osteocytes (dendritic)
processes, which run inside lacunar cannaliculi. These processes
may have the potential to stimulate bone resorption.78 79 It has
long been recognised that mechanical stress induced by weight-
bearing exercise increases osteoblast activity. Indeed, the
absence of mechanical stimulation resulting from prolonged
immobilisation or microgravity causes severe bone loss.80 81
There is an emerging consensus that osteocytes act as
mechanosensory cells and lacuno-canaliculae carry signalling
molecules that are responsible for maintenance of bone
structure and mass.82–84 This model has been proposed to
explain how mechanical loading induces biochemical transmis-
sion that promotes bone formation and remodelling.
Osteocytogenesis
The process of osteocyte differentiation or osteocytogenesis,
whereby osteoblasts become encased in mineralised bone matrix
is not yet understood, but there have been some important
observations. The most abundant matrix protein in the
osteocyte environment is type-I collagen. Osteocyte phenotype
and the formation of osteocyte processes has been shown to be
dependent on cleavage of type-I collagen.77 85 Osteocytes from
metalloproteinase MT1-MMP (2/2) mice have a significantly
reduced number and length of dendritic processes; MT1-MMP is
a membrane-anchored proteinase that can cleave collagens type
I, II, and III, fibrin, fibronectin, and other matrix molecules.77 85
Changes in osteocytes dendrite number have been suggested to
effect osteocyte function and viability, as well as the mechanical
properties of bone. The fluid flow shear stress-related osteocyte
dendrite lengthening has been shown to be due to protein E11.
E11 protein, which is also known as Gp38, podoplanin, RTI40,
and T1a, plays a role in the formation of dendritic processes; its
expression is increased in response to fluid flow.86
A number of matrix proteins, such as dentin matrix protein 1
(Dmp1), matrix extracellular phosphoglycoprotein or osteo-
cytes/osteoblast factor 45 (MEPE/OF45), and sclerostin increase
in expression once the osteoblast begins to transform into an
osteocyte.87 89 DMP1, an acidic phosphorylated extracellular
matrix protein, is a member of a family of proteins called
SIBLING (Small; Integrin-Binding LIgand, N-linked
Figure 4 Canonical Wnt/catenin pathway in osteoblast differentiation.
Wnt/b-catenin pathway signals through LRP-5 or LRP-6, leading to
inhibition of glycogen synthase kinase (GSK)-3, thereby preventing
phosphorylation and degradation of b-catenin. The accumulated b-
catenin translocates to the nucleus and activates T cell-specific
transcription factors. Wnts also activate non-canonical pathways that
include the G-protein and dishevelled (Dsh) mediated c-Jun NH2-terminal
kinase (JNK) signalling, but the significance of the non-canonical
pathways is unclear. The extracellular secreted proteins (WIF-1 and
Sfrps) inhibit by binding Wnt or by blocking LRP5/6 (Dkks or sclerostin).
Review
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Glycoprotein).90–92 Other members include MEPE and bone
sialoprotein (BSP), osteopontin (OPN), and dentin sialopho-
sphoprotein (DSPP); all bind hydroxyapatite and possess RGD
sequence. OPN and DMP1 bind CD44, which interacts with the
ERM (ezrin, radixin, moesin) family of adapter proteins that
link to actin in the cytoskeleton.93 94 That DMP1 may have an
important role in osteocyte maturation is evident from its high
level of expression in osteocytes; particularly in the dendritic
processes of these cells, and increased expression in response to
mechanical loading.88 Osteocytes from DMP1-null mice show
abnormalities in osteocyte morphology and severe impairment
in mineralisation. DMP1 2/2 mice and human autosomal
recessive hypophosphataemic rickets display similar pheno-
types, with raised FGF23 producing renal phosphate-wasting
associated rickets. In contrast, MEPE null mice have raised
osteoblast activity, increased bone mass, and are resistant to
aging-associated trabecular bone loss, suggesting that it has an
inhibitory role in bone formation.88 90 91
Bone mechanoreceptor cells
The transformation of mechanical stress into biochemical
signals occurs in osteocytes and osteoblasts and involves a
variety of membrane proteins, including integrins, connexins
and stretch-activated ion channels. Potential biochemical
intracellular signal mediators include IP3 and intracellular
calcium, cAMP, guanine regulatory proteins and MAPK.95–99
Integrins are transmembrane dimers made of a and b subunits;
the b subunit has also been reported in osteocytes.100 Fluid flow
up-regulates b1 expression and activates avb3 which co-localises
with c-src.101 Integrin signalling activates MAPK via b1 integrin
and FAK dependent tyrosine phosphorylation in endothelial
cells. FAK brings about MAPK activation via interaction with c-
src, Grb2 and the small GTPase Ras.102 103 FAK activates the c1
isoform of PL, leading to intracellular calcium mobilisation. This
pathway may be important in osteocytes since fluid induced
calcium mobilisation has been shown to require PLC mediated
IP3 release. Mechanical stimulation increases expression of
connexins, membrane-spanning proteins that form regulated
channels; this allows the direct exchange of small molecules
with adjacent cells, resulting in intercellular communication
between cells. It has been shown that mechanical stimulation
increases expression of connexins.104 Connexins can also form
regulatory hemi-channels between the cell and its extracellular
environment. Shear stress leads to the modulation of release of
nitric oxide and eicosanoid from osteoblasts and osteocytes,
which may be due to activation of nitric oxide synthase.105 106
Osteoclasts
The respective bone resorbing and forming actions of osteoclasts
and osteoblasts are finely coupled, so that in a healthy adult
bone mass remains remarkably stable. There are however many
disease states, such as osteoporosis, Paget’s disease of bone, bone
cancer metastases and inflammatory arthritis, where this fine
equilibrium is disrupted due to a net increase in osteoclast bone
resorbing activity. In view of the critical role of osteoclasts in
diverse pathology, there has been immense effort aimed at
understanding the biology of this unique cell.
Osteoclastogenesis
Osteoclasts are end-differentiated multinucleated cells of
monocyte/macrophage lineage that are formed to carry out
the unique function of resorbing bone matrix. It had been
apparent for decades that in vitro differentiation of monocytes
to osteoclasts could only take place when co-cultured with
osteoblasts or other stromal cells.107 Subsequent investigations
have shown that osteoclastogenesis is critically dependent on
two key cytokines, namely RANKL (receptor activator of
nuclear factor-kB ligand), also known as TRANCE (TNF-related
activation-inducing cytokine) and M-CSF (monocyte-colony
stimulation factor). M-CSF is thought to be critical for the
proliferation of the osteoclast progenitors, while RANKL
directly controls the differentiation process by activating
RANK (receptor activator of nuclear factor-kB).108–111 It is now
emerging that RANK cooperates with other receptors: OSCAR
(osteoclast-associated receptor) and a triggering receptor
expressed on myeloid cells (TREM)-2) (fig 5).112–114 OSCAR is
an immunoglobulin-like receptor and, like RANKL, is involved
in osteoblast–osteoclast interaction. OSCAR acts via an adaptor
molecule FcRc, which has an immunoreceptor tyrosine-based
activation motif (ITAM) that is critical for the activation of
calcium signalling.115 DAP12, another ITAM-harbouring adap-
tor, is also involved in the formation and function of osteoclasts.
There is emerging evidence for cooperation between the
signalling that occurs via RANK, OSCAR/PIR-A and TREM-2.
Stimulation of RANK and of the immunoglobulin-like receptors
cooperatively phosphorylates ITAM.116 The precise mechanism
as to how RANK induces osteoclastogenesis in cooperation with
ITAM signalling is not fully understood. It is partly explained
by the observation that RANKL leads to an increased
phosphorylation of ITAM and increases expression of immu-
noglobulin-like receptors such as OSCAR, thereby augmenting
the ITAM signal. In the absence of a functional DAP12 protein,
FcRc mediated co-stimulatory signals can restore weak osteo-
clast differentiation. The identity of ligands that bind to
DAP12- and FcRc-associated receptors, leading to the phosphor-
ylation of their ITAM motif, is not known. The phosphorylated
tyrosine residues in ITAM interact with the SH2 domain of Syk
family kinase, and activate phospholipase Cc (PLCc), leading to
transient increase in intracellular calcium and the induction of
nuclear factor of activated T-cells-2 (NFAT2, also known as
NFATc1).117 118
RANK–RANKL interaction activates NFATc1 by an alternate
pathway involving TRAF-6, c-Jun, c-Fos and p38.119–124 NFATc1
is critical for osteoclastogenesis as its over-expression abolishes
the RANKL requirement for osteoclastogenesis, and NFATc1
(2/2) monocytes fail to form osteoclasts. RANK–RANKL
signalling induces intracellular Ca2+ oscillations, which are
regulated by a G-protein (RGS10). RGS10-null mice have
impaired osteoclast differentiation resulting from the loss of
[Ca2+]i oscillation regulation.125 This shows that RANKL-evoked
G-protein (RGS10) mediated Ca2+ oscillations lead to calmodu-
lin and calcineurin-dependent NFATc1 activation.125
Osteoclast bone resorption
Osteoclasts predominantly express avb3 integrin, which recog-
nise the RGD-containing matrix proteins, such as OPN and
BSP.126 The occupancy of vb3 is associated with intracellular
signalling, and increased intracellular Ca2+ and tyrosine phos-
phorylation and free radical production, resulting in osteoclast
activation.127–129 Osteoclast-bone interaction leads to the forma-
tion of the osteoclast clear zone and the organisation of actin-
based adhesion structures named podosomes. Podosomes are
comprised of an F-actin core surrounded by vinculin, talin,
actinin, fimbrin, gelsolin and vimentin.130 Extracellular matrix
interaction with avb3 induces c-src dependent tyrosine phos-
phorylation, PYK2 activation and its translocation to podo-
somes. Some of the cytoskeletal changes are mediated by the
Review
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Rho-GTPases.129 131–133 The process of osteoclast migration,
polarisation and activation involves a number of other signalling
molecules, such as Crkl,11, c-Cbl, p130 Cas, leupaxin PI3-K,12,
RhoA,13 and PYK-2, and is also dependent on Wiskott–Aldrich
syndrome protein (WASp).134 WASp has been identified in the
sealing ring of resorbing osteoclasts, and co-localisation with c-
Src, PYK2, PSTPIP and PTP-PEST. PTP-PEST coordinates the
formation of the sealing ring and thus the bone-resorbing
function of osteoclasts.134–136
A bone-resorbing osteoclast shows polarity; degradation
products of collagen and other matrix proteins are transported
by transcytosis to the basolateral membrane.137 138 However, the
mechanisms involved in disposal of Ca2+ and phosphate, which
accumulate within the resorption hemivacuole, are unclear. Ca2+
is continually transported to the basolateral surface and was
postulated to be selectively disposed by channels and transpor-
ters.139–143
Osteoimmunology
Recent efforts are beginning to define the nature of the
interactions between the immune and skeletal systems (fig 6).
The realisation of the intricate nature of this interaction has
been supported by the fact that a number of cell surface
receptors, cytokines and signalling pathways serve a critical role
both in the immune and skeletal systems. The close interaction
between immune progenitors and skeleton is facilitated by their
proximity in the bone marrow. Therefore, osteoimmunology, a
discipline that encompasses the complex interactions and
overlapping functions of the immune system and bone cells
has emerged over recent years.
T cells
T cells rapidly up-regulate surface expression of RANKL on
activation, and are therefore capable of regulating osteoclast
differentiation and activity. Indeed, activated T cells have been
shown to promote osteoclastogenesis in vitro, mediate bone
erosion in inflammatory joint disease and play an essential role
in the pathogenesis of osteoporosis in ovariectomised mice.144–146
In contrast, resting T cells actively suppress osteoclastogenesis
in a cell:cell contact independent manner.147 RANKL is also
expressed on memory T cells, but not on naive T cells, but the
physiological significance of such differential expression is
unclear.148 Apart from RANKL, T cells produce many other
cytokines that modulate osteoclast activity and osteoclastogen-
esis; TNF-a, IL-6 and IL-17 are stimulatory, while IL-4, IL-13 and
IL-10 are inhibitory.149 Since the range of cytokines produced by
different T cell subsets show considerable variability, so does
their effect on osteoclast number and activity. In addition to
their effect on osteoclast function, T cells may also interact
with osteoblasts directly and exert effects on bone turnover
indirectly via their interactions with dendritic and B cells.150 151
B cells
The role of other immune cell types on bone metabolism is
poorly understood, although emerging data suggest that the B
Figure 5 Molecular signalling involved
in osteoclast differentiation. On activation
RANK interacts with adapter protein
TRAF6, which acts downstream to
activate MAP kinases and NF-kb. For the
RANK signal to be effective, co-signalling
from the immunoreceptors OSCAR and
TREM2 is required. OSCAR and TREM
interact with FcRa˜ and with FcRc
adapters that possess ITAM motifs and
activate Syk kinases which in turn
activate PLCc. The resulting mobilisation
of Ca2+ from the intracellular stores
activates calcineurin, which then
dephosphorylates the transcription factor
NFATc1. NFATc1 translocates to the
nucleus and, acting in concert with c-fos,
promotes expression of key osteoclast
genes. The tyrosine kinase-family
receptor c-fms and its ligand M-CSF are
essential for the survival and proliferation
of the progenitors cells.
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cell may be important.151 For instance, it has been reported that
B cell progenitors are capable of differentiating into osteoclasts
in vitro, and that peripheral blood B cells suppress osteoclasto-
genesis. Recently, it has been shown that B cells are a source of
osteoprotegerin (OPG), and that B-cell deficient mice have
reduced bone mass, which can be reversed by adoptive transfer
of B cells.151–153
B7-H3, a widely expressed member of the B7 family of the Ig
superfamily of proteins, is expressed on the surface of the
antigen-presenting cells; it down-regulates T cell functions by
interacting with a yet unidentified membrane-bound ligand on
T cells. B7-H3 and its unknown counter-receptor have been
shown to play a positive regulatory role in bone formation as
well as in bone–immune system interaction.154 155
Cytokines and growth factors
Many cytokines are important regulators of osteoclast and
osteoblast function, and a majority of these cytokines are
produced by cells of the immune system.156 The precise
mechanisms of how these cytokines regulate osteoblast and
osteoclast activities have not been fully defined; most act
indirectly by regulating the interactions between osteoclasts
and osteoblasts. For instance, many cytokines have been shown
to regulate the expression of RANK and RANKL on osteoclast
and osteoblasts respectively, or modulate the intracellular
signalling mediated by RANK. In general, pro-inflammatory
cytokines, such as IL-1, TNF-a, and IL-6, appear to act
synergistically on osteoclastogenesis and promote osteoclast
function.157–162 Table 1 summarises the effects of the various
cytokines on bone metabolism and the possible underlying
mechanism(s) of action.
TNF-a enhances RANKL-mediated stimulation of osteoclasts
by activating NF-kB.158 TNF-a also enhances the mobilisation of
osteoclastogenesis progenitors from bone marrow and inhibits
osteoblastic activity.159 Like TNF-a, IL-1 activates NF-kB, which
promotes osteoclast survival and induces RANKL expression on
osteoblasts.160 There are two forms of IL-1, IL-1a and IL-1b, but
their biological activities are indistinguishable; cells of mono-
cytic lineage on activation predominantly produce IL-1b, while
IL-1a is released by dying cells and is not normally found in the
circulation.161 Osteoblasts and stromal cells are the main source
of IL-6 in bone; the effect of IL-6 on bone resorption is mediated
primarily via stimulation of osteoclasts.162 163 IL-17, a key
cytokine that mediates autoimmune inflammatory arthritis,
also augments osteoclastogenesis.164 In contrast, Th2 cytokines
such as IL-4, IL-13 and IL-10 suppress osteoclastogenesis and
osteoclast activation.165 Interestingly, a recent report suggests
that IL-4 may play an important role in CD4+CD25+Foxp3+
regulatory T cell-mediated suppression of osteoclastogenesis.166
Another class of cytokines that inhibits osteoclastogenesis is the
interferons. IFN-b suppresses RANKL-induced expression of c-
Fos; IFNb2/2 mice have increased osteoclast activity and are
osteoporotic.167
Osteoblast regulation of energy metabolism
Recent evidence shows that osteoblast function may contribute
to obesity and glucose intolerance. This suggests that the
skeleton exerts an endocrine regulation of energy metabolism
and thereby may contribute to the onset and severity of
metabolic disorders. Esp (also known as Ptprv), a receptor-like
protein tyrosine phosphatase termed OST-PTP that is expressed
in osteoblasts has been shown to regulate insulin secretion.168
Mice lacking Esp in osteoblasts have increased b-cell activity
that protects them from induced obesity and diabetes. These
phenotypes are corrected by deleting one allele of osteocalcin,
suggesting that osteocalcin may also play a role. Osteocalcin
null mice are glucose intolerant; osteocalcin promotes prolifera-
tion of pancreatic b-cells and adiponectin expression in
adipocytes and b-cells.169
Figure 6 Interactions between the
immune system and bone. OB play a key
role in regulating osteoclastogenesis and
activation of OC (1). T cells also regulate
these processes both directly via RANKL–
RANK interaction and production of
cytokines (2), and indirectly via their
effects on OB (5) and DC (6). The overall
effects may be stimulatory or inhibitory,
depending on the T cell subsets and the
cytokines produced as well as other local
factors. DC produce cytokines that can
promote or suppress osteoclastogenesis
(3); DC also interact with T cells (6). It
has also been suggested that DC can be
transformed to become OC in
inflammatory milieu (4). Other immune
cell types may affect OC function by
interaction with T cells and DC (7). The
direct effects of other immune cell types
in osteoclastogenesis and OC activation
have not been extensively investigated
(dotted arrow). Finally, osteocytes may
play a role in regulating haemopoiesis (8)
and regulate osteoblast activity (9). OIC,
other immune cells; T, T cells; DC,
dendritic cells; OC, osteoclasts; OB,
osteoblasts; OCP, osteoclast precursors;
HSC, haemopoietic stem cells.
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SUMMARY
Bone is a specialised tissue designed to provide sufficient
strength to withstand mechanical forces, but yet to be light
enough to allow mobility. It has a complex structure and
undergoes constant remodelling. The remodelling process is
undertaken by the basic multicellular unit of bone, which
comprises osteocytes, osteoclasts and osteoblasts. They act in a
coordinated manner to form or resorb bone as necessary. Their
activation is controlled by mechanical forces, apoptosis,
hormones, cytokines and local factors (fig 7). Osteocytes play
a central role in the response to shear stress and micro-fracture,
regulating bone remodelling via their dendritic processes and by
apoptosis. The differentiation of progenitor cells into osteo-
blasts and osteoclasts is also under the control of complex
regulatory mechanisms. There is growing evidence of interac-
tion between the immune system and bone cells. A number of
recent breakthroughs have shown that bones cells are not
merely involved in bone remodelling and maintenance of bone
mass, but have a number of critical functions. Among these
newly described functions are the role of skeleton in energy
metabolism, regulation of immunity and blood phosphate
homoeostasis.
Competing interests: None declared.
Table 1 Effects of various cytokines produced by the immune system on bone metabolism
Cytokines
Overall effect
on bone loss
Possible mechanisms
Effect on OC Effect on OB
RANKL q Increases OC generation
Activates OC
Inhibits OC apoptosis
IL-1 q Increases OC generation Induces RANKL
Activates OC
IL-4 Q Inhibits OC generation
Down-regulates RANK
IL-6 q Increases OC generation Induces RANKL
IL-7 q (Indirect, via T cell-mediated mechanisms)
IL-10 Q Inhibits RANK signalling
IL-12 Q (Indirect, via induction of IFN-c)
IL-17 q Increases OC generation Induces RANKL
Induces RANK
IL-18 Q (Indirect, via induction of IFN-c)
TNF-a q Increases mobilisation of OCP from bone marrow inhibits OB
Activates OC
IFN-a/b Q Inhibits RANKL signalling
IFN-c ? q See text See text
TGF-b ? q See text See text
M-CSF q Increases OC survival and proliferation
GM-CSF Q Inhibits RANKL signalling
MCP-1 q Promotes osteoclast fusion and activation
OPG* Q Decreases OC generation
Inhibits RANKL signalling
Increases OC apoptosis
*A decoy receptor rather than cytokine.
OC, osteoclasts; OB, osteoblasts; OCP, osteoclast precursors; RANKL, receptor activator of nuclear factor kB ligand; IL, interleukin;
TNF, tumour necrosis factor; IFN, interferon; TGF, transforming growth factor; M-CSF, macrophage colony stimulation factor; GM-
CSF, granulocyte macrophage colony stimulation factor; MCP, monocyte chemoattractant protein; OPG, osteoprotegrin.
Figure 7 Mediators involved in the
intercellular interactions between bone
cells.
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